

## Efficacy of Immunization with Outer Membrane Proteins for Induction of Pulmonary Clearance of Nontypeable *Haemophilus Influenzae* in a Rat Respiratory Model

Farhad Esmaily<sup>1</sup>, Farhad Vaezzadeh<sup>2</sup>, and Mohammad Kazem Sharifi-Yazdi<sup>3</sup>

<sup>1</sup> Department of Microbiology, Razi Vaccine and Serum Research Institute, Karaj, Iran

<sup>2</sup> Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

<sup>3</sup> Department of Medical Laboratory Sciences, Faculty of Para medicine, Tehran University of Medical Sciences, Tehran, Iran

Received: 26 February 2006; Received in revised form: 16 March 2006; Accepted: 16 March 2006

### ABSTRACT

Three strains of nontypeable *Haemophilus influenzae* namely NTHi-I, NTHi-II and NTHi-III were isolated from the sputum of patients with bronchitis and identified by biochemical, serological and electron microscopy. The polypeptide patterns of isolates were compared and found to have similar sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) polypeptide patterns, although some of the bands were specific in some strains. A similar comparison was made on extracted outer membrane proteins (OMPs) on the above mentioned strains, using Triton X-100 and sodium dodecyl sulphate (SDS). It was found that the polypeptides with molecular weights of 70, 42, 33 and 27 KDa were identified as P1, P2, P4 and P5 respectively. The protein estimation of crude OMPs from the three strains were calculated, and OPM-I prepared from NTHi-I showed the highest amount of protein and was chosen for its immunogenicity in a rat respiratory model.

The efficacy of immunization with OMP was determined by enhancement of pulmonary clearance of live bacteria in the rat lung. A significant protective immune response induced by OMP was observed by enhanced respiratory clearance of nontypeable *H. influenzae* following mucosal immunization.

**Key words:** Nontypeable *Haemophilus influenzae*; Outer membrane protein; Pulmonary clearance

### INTRODUCTION

Unencapsulated or nontypeable *Haemophilus influenzae* (NTHi) is a common cause of wide range of human diseases including tracheobronchitis, pneumonia, epiglottitis, and otitis media.<sup>1-3</sup>

Unlike *Haemophilus influenzae* type b for which a highly successful vaccine is available, there is no vaccine available that can protect the occurrence of these NTHi infections. Outer membrane proteins (OMPs) and lipooligosaccharide (LOS) are major surface antigens of NTHi and considered as a potential vaccine candidates.

The search for an effective vaccine has focused on components of the outer membrane proteins, and most vaccine development efforts have been directed towards

---

**Corresponding Author:** Farhad Vaezzadeh, MD, PhD;  
Department of Pathobiology, School of Public Health, Tehran  
University of Medical Sciences, Tehran, Iran. Tel: (+98 21) 8895  
4913, Fax: (+98 21) 8895 4913, E-mail: Fvaezzadeh@sina.tums.ac.ir

integral outer membrane proteins component. Several outer membrane proteins such as P1, P2, P4 and P6 have been investigated, and P6 has been proposed as a likely candidate for effective vaccine against NTHi infections.<sup>4,7</sup> In this study attempt was made to extract and purify the crude OMP from NTHi and to assess the immunogenicity and protective activity of the extracted NTHi OMP by clearance of NTHi from the rat respiratory tract.

## MATERIALS AND METHODS

### Bacterial Strains and Growth

Three strains of NTHi namely NTHi-I, NTHi-II and NTHi-III were isolated from sputum of patients with bronchitis. The isolates were grown on different culture media, and identified by biochemical tests according to standard method.<sup>8</sup> The NTHi ATCC 860295 was used as positive control strain. The biotypes of isolated strains were determined using indole, ornithine, urease, oxidase and catalase tests.

### Electron Microscopy

The electron microscopy was used for the confirmation of lack of capsules (unencapsulated) of strains, by the electron microscopy unit of Razi institute.

### Preparation of OMP by SDS Method

The bacteria were grown overnight at 37°C in 5% CO<sub>2</sub> on Levital agar, purified colonies were transferred into brain heart infusion (BHI) broth, supplemented with 50 ml of defibrinated horse blood per liter of agar at 37°C in 5% CO<sub>2</sub>. 70 mg wet weight culture were obtained from each isolates. The OMP were prepared with a few modifications as described previously<sup>9</sup> and designated as OMP-I, OMP-II, and OMP-III respectively.

Briefly the bacterial suspension was transferred into sonicating tube. The cells were sonicated in sonicating tube located in a Flask of ice crashed for 10 min with 10 sec intervals between each minute. The suspension was centrifuged at 10000g for 30 min at 4°C and the supernatant was collected and centrifuged again for 1 h. The clear pellet was suspended in 4ml of 10 mM Hepes buffer containing 2% triton X-100. 2ml of 2% SDS was added and was left at 56°C for 15 min, the suspension was centrifuged in the same manner for 1 h. The sediment which consisted of protein complex and peptidoglycan was suspended in 1 ml of distilled water

and dialyzed against 2ml of 5M NaCl containing 2% SDS and it was left overnight at 37°C. The dialysate was centrifuged at 5000 g at 4°C for 10 min; the supernatant was dialyzed three times against distilled water for 48h at room temperature, thus SDS and NaCl was separated from protein complex.

### Protein Concentration Determination

Protein concentrations of various strains of NTHi were determined according to lowry method<sup>10</sup> with bovine serum albumin as the standard and folin phenol reagent.

### Electrophoresis

Using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), the polypeptide patterns of the three isolates and the crude OMP extracts, were determined as described previously.<sup>11</sup> To determine the molecular weights of the protein components, high and low molecular weight markers were used.

### Immunization for Pulmonary Challenge

Immunization was performed as described previously.<sup>12</sup> Briefly, the male rats aged between 8 and 10 weeks were sedated with halothane given intraperitoneally (ip), and the small intestine was exposed to enable inoculation of intestinal Peyer's patches with 1:1 mixture of immunogen emulsified with incomplete Freund's adjuvant (IFA), and phosphate buffered saline (PBS). The immunogen protein was prepared by emulsifying 200 and 800 µg/ml of protein respectively. Control groups included, negative control in which rats receiving IFA and PBS only and positive control immunized with killed bacteria of the homologous NTHi strain.


The bacteria were killed in 1% (w/v) paraformaldehyde in PBS and incubated at 37°C for 2 hours. The bacteria were washed four times in PBS and the concentration was adjusted to a bacterial equivalent to  $2 \times 10^{10}$  per ml. Killing was verified by plating onto agar and overnight culture, the bacteria were then emulsified in a 1:1 with IFA so that each animal received approximately  $5 \times 10^8$  bacteria. Fourteen days post immunization, rats received a boost, delivered intratracheally to the lungs, of 15 µg of OMP-I in PBS. A live NTHi challenge was delivered 21 days postimmunization intratracheally (pulmonary challenge) as described previously.<sup>12</sup> For the challenge each rat

received approximately  $5 \times 10^8$  CFU. Viability count was confirmed by concurrent overnight culture onto chocolate blood agar.

## RESULTS


### Electron Microscopy

The electron micrograph isolates of NTHi for the confirmation of lack of capsules (unencapsulated) are shown in figure 1.



**Figure 1. Electron micrograph of an unencapsulated strain of NTHi-I Satellitism phenomenon**

The need of NTHi to V factor for its growth, was provided by using *S. aureus* to produce V factor figure 2.



**Figure 2. Satellites phenomenon of NTHi using *S. aureus***

### Results of Serological Tests


#### Agglutination

Two sera of polyvalent anti-serum against NTHi and monospecific anti-serum against biotype II were used. The results showed all the isolates were unencapsulated and of biotype II.

The biotype of isolates were confirmed by indole (+), ornithine, (-)urease(+), oxidase(+) and catalase (+).

### The SDS-PAGE Results

The comparison between polypeptide patterns of isolated strains showed similarity, although the densities and molecular weights of some of the bands were specific. A polypeptide with 48 KDa was seen only in standard strain, while bands with molecular weights of 75, 78 and 72 KDa were seen in NTHi-I, NTHi-II and NTHi-III respectively, figure 3.



**Figure 3. Comparison between polypeptide patterns of three strains of NTHi-I, NTHi-II, NTHi-III and strain 860295**

Polypeptide patterns of OMPs extracted from all strains showed bands with molecular weights of 70, 42, 33 and 27 which were common in all strains as P1, P2, P4 and P5 respectively, figure 4.


### Protein Concentration Determination

Protein concentration of OMPs for all stains were determined as follow, 1.5, 0.9 and 1.2 mg. for OMP-I, OMP-2 and OMP-3 respectively. OMP-I with the highest amount (1.5) mg were chosen for the in-vitro studies.

### Clearance of NTHI after Immunization with OMP-I

4 hours post-challenge, bacterial clearance in bronchoalveolar lavage (BAL) fluid and lung homogenates were compared with those for the non-immune rats. The results showed that immunization with

15 µg of OMP-1 per rat resulted in a significantly enhanced clearance of NTHi-I from the BAL fluid and lung homogenates ( $P<0.001$ ) (table 1).



**Figure 4.** Comparison between OMPs extracted from three strains of NTHi-I, NTHi-II, NTHi-III, on tracks 1, 2, 3.

**Table 1.** Pulmonary clearance of NTHi-I following mucosal immunization with OMP-1 and challenging with homologous NTHi-I strains

Rat group	Mean NTHi-I recovered 4 hours post challenge ( $\log^{10}$ CFU) $\pm$ SEM (% clearance)	
	BAL	Lung
Nonimmune (negative control)	$6.52 \pm 1.304$	$6.22 \pm 1.30$
Immunized with killed bacteria (positive control)	$5.45 \pm 1.140$	$5.26 \pm 1.14$
Immunized with OMP-I	$4.5 \pm 0.212$	$4.48 \pm 1.7$

## DISCUSSION

Many factors contribute to both pathogenesis of bacterial bronchitis and the host's ability to resolve these infections. It has been shown by many laboratories, that the greatest likelihood for the successful development of a nontypeable *Haemophilus influenzae* directed vaccine relies upon the careful selection of conserved and protective immunogenes.<sup>13</sup> Ideally the vaccine must induce a balanced and broadly protective immune response in very young children. Because of

the increased incidence of antibiotic resistant NTHi in recent years<sup>14</sup> have been the thought for the development of an effective vaccine against this bacterium and considered as an important goal for public health.<sup>15</sup> For this reason we isolated three strains of NTHi namely NTHi-I, NTHi-II and NTHi-III from children with bronchitis, and the comparison was made between the polypeptide bands of these strains. It showed similarity between polypeptide bands, although the existence and the density of some bands were variable e.g: three bands with molecular weights of 75, 78, and 72 KDa only existed in NTHi-I, NTHi-II and NTHi-III, respectively.

We extracted OMPs from all strains and were compared by SDS-PAGE. The polypeptide patterns of all OMPs were very similar and bands with 27, 33, 42 and 70 KDa were identified as P1, P2, P4 and P5 respectively, which were common in all strains. The protein estimation of crude OMPs were calculated and was found that the protein of OMP-I extracted from NTHi-I had the highest amount and was chosen for in-vitro studies. By using mono specific antibody, and indole (+), ornithine (-), urease (+), oxidase (+) and catalase (+) test the isolates were classified as biotype II. This type is the most common cause of bronchitis in children and adults.<sup>16</sup>

There is currently considerable interest in OMP of nontypeable *H. influenzae* as a vaccine candidate against NTHi. The protection of major outer membrane proteins of NTHi such as P1, P2, P4, P5 and particularly P6 have been shown to enhance pulmonary clearance in rat and chinchilla upon direct challenge, suggesting as a suitable candidate for vaccine.<sup>17-19</sup> In this study, we have demonstrated that mucosal immunization with major OMP of nontypeable *H. influenzae* in rat, resulted in significant pulmonary clearance in bronchoalveolar lavage (BAL) and lung ( $P<0.001$ ). Our results is in correlation with previous findings,<sup>20</sup> and provides sufficient evidence that OMP has the potential for the protection against NTHi infections.

## ACKNOWLEDGEMENTS

This research has been supported by Tehran University of Medical Sciences and Health Services grant No. 130/9023.

## REFERENCES

1. Faden H, Brodsky L, Bernstein J, Stanievich J, Krystofik D, Shuff C, et al. Otitis media in children: local immune response to nontypeable *Haemophilus influenzae*. *Infect Immun* 1989; 57(11):3555-9.
2. Musher DM, Kubitshek KR, Crennan J, Baughn RE. Pneumonia and acute febrile tracheobronchitis due to *Haemophilus influenzae*. *Ann Intern Med* 1983; 99(4):344-50.
3. Foxwell AR, Kyd JM, Cripps AW. Nontypeable *Haemophilus influenzae*: Pathogenesis and prevention. *Microbiol Mol Biol Rev* 1998; 62(2):294-308.
4. Badr WH, Loghmanee D, Karalus RJ, Murphy TF, Thanavola Y. Immunization of mice with P6 of NTHi: Kinetics of the antibody response and IgG subclasses. *Vaccine* 1999; 18(1-2):29-37.
5. Murphy TF, Bartos LC, Campagnari AA, Nelson MB, Apicella MA. Antigenic characterization of the P6 protein of nontypeable *Haemophilus influenzae*. *Infect Immun* 1986; 54(3):774-9.
6. Bandi V, Apicella MA, Mason E, Murphy TF, Siddigi A, Atmar RI, et al. Nontypeable *Haemophilus influenzae* in the lower respiratory tract of patients with chronic bronchitis. *Am J Respir Crit Care Med* 2001; 164(11):2114-9.
7. Murphy TF, Bartos LC, Rice MB, Nelson KC, Duda S, Apicella MA. Identification of a 16,600-Dalton outer membrane protein on nontypeable *Haemophilus influenzae* a target for human serum bactericidal antibody. *J Clin Invest* 1986; 78(4):1020-7.
8. Kilian M. *Haemophilus*. In: *Manual of clinical microbiology*. Washington, DC: American Society of Microbiology, 1980: 330.
9. Van Gelder P, Cock HD, Tommasson J. Detergent induced folding of the outer membrane protein Pho E a pore protein induced by phosphate limitation. *Eur J Biochem* 1994; 226(3):783-7.
10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J Bio Chem* 1951; 193(1):265-75.
11. Ojanen T, Helander IM, Haahtela K, Korhonen TK, Laakso T. Membrane protein and Lipopolysaccharide in pahtovars of *Xantomomas campestris*. *American society for microbiology. APP Env Microbial* 1993; 59(12):4143-51.
12. Wallace FJ, Clancy RL, Cripps AW. An animal model demonstration of enhanced clearance of nontypeable *Haemophilus influenzae* from respiratory tract after antigen stimulation of gut-associated lymphoid tissue. *Am Rev Respir Dis* 1989; 140(2):311-6.
13. Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, et al. Development of nontypeable *Haemophilus influenzae* (nontypeable *H. influenzae*). *Vaccine* 2000; 19(Suppl. 1):5108-15.
14. Brook I, Gober AE. Resistance to antimicrobials used for therapy of otitis media and sinusitis. *Ann Otol Rhinol Laryngol* 1999; 108 (7 Pt 1):645-47.
15. KYD JM, Crips AW. Potential of a novel protein, OMP26, from nontypeable *Haemophilus influenzae* to enhance pulmonary clearance in a rat model. *Infect Immun* 1998; 66(5):2272-78.
16. Barenkamp SJ, Munson RS, Granoff DM. Outer membrane protein and isotype analysis of pathogenic nontypeable *Haemophilus influenzae*. *Mol Microbiol* 1982; 36(2):535-40.
17. Kyd JM, Dunkley ML, Cripps AW. Enhanced Respiratory clearance of nontypeable *Haemophilus influenzae* following mucosal immunization with P6 in rat model. *Infect Immun* 1995; 63(8):2931-40.
18. Murphy TF, Bartos LC. Human bactericidal antibody response to outer membrane protein P2 of nontypeable *Haemophilus influenzae*. *Infect Immun* 1988; 56(10):2673-79.
19. Murphy TF, Nelson MB, Apicella MA. The P6 outer membrane protein of nontypeable *Haemophilus influenzae* as a vaccine Antigen. *J Infect Dis* 1992; 165(Suppl. 1):5203-5.
20. Green BA, Vazquez Me, Zlotnick Aw, Qviale-Reape G, Swarts JD, Green I, et al. Evaluation of mixtures of purified *Haemophilus influenzae* outer membrane proteins in protection against challenge with nontypeable *H. influenzae* in the chinchilla otitis media model. *Infect Immun* 1993; 61(5):1953-7.